French and Swiss researchers have uncovered the genetic and energetic characteristics of leukemic stem cells that are responsible for acute myeloid leukemia (AML) and suggest that blocking a specific iron utilization process of these cells provides an avenue for new therapeutic strategies to fight this disease. New approaches are desperately…

Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. Now, scientists at Purdue University’s College of Science and collaborators have developed a patent-pending compound called HSN748 to treat drug-resistant AML. Their findings are published in the Journal of Clinical Investigation in…

Researchers have been awarded new funding to develop therapies against a form of pediatric leukemia which generally has a poor prognosis. A team led by John H. Bushweller, PhD, of the University of Virginia School of Medicine, is leading the effort to create new therapeutic options for acute myeloid leukemia…

Sponsored content brought to you by ‘It was amazing to discover that AML evolution is mainly driven by methylation alterations that affect low density CpGs regions in the gene body of master transcription factors. These findings completely changed our point of view on epigenomic alterations of AML.’ — Alberto Magi, Department…

Research carried out at Cold Spring Harbor Laboratory shows that a phosphatase protein known as SCP4 is essential for the survival of acute myeloid leukemia (AML) cancer cells. The research team hope their discovery will lead to new therapeutic options for this aggressive form of blood cancer. AML is caused…

Research from the U.K.’s University of Birmingham explains how mutations in the RUNX1 gene can influence blood cell development and cause different types of cancer and other blood disorders. The RUNX1 gene encodes a protein that guides the way hematopoietic stem cells change into adult blood cells. Mutations in this…

A team of investigators at the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn have just published findings from a new metastudy that found artificial intelligence can detect one of the most common forms of blood cancer—acute myeloid leukemia (AML)—with high reliability. The research teams’ approach was…

A team of investigators led by scientists at St. Jude Children's Research Hospital and the Washington University Pediatric Cancer Genome Project (PCGP) has published a comprehensive map of the genomic landscape for the form of acute myeloid leukemia (AML) called core-binding factor acute myeloid leukemia (CBF-AML). This new work reveals…

Syndax’s revumenib showed promise in advanced acute leukemias with KMT2A rearrangements or mutant NPM1, according to findings from the Phase I AUGMENT-101 trial published this week in Nature. Formerly SNDX-5613, revumenib is an oral small-molecule inhibitor of the menin (MEN)-KMT2A interaction. Another study this week, also in Nature, explained the how MEN1 mutations play…

A retrospective survival analysis conducted by researchers at Baylor College of Medicine and Texas Children’s Hospital found that children with acute lymphoblastic leukemia (ALL) who lived along the Texas border with Mexico were more likely to die within five years than those living in other areas of the state. The…

A type of chronic blood cancer called myeloproliferative neoplasms (MPN) can often be present in patients in a relatively benign state for years. Some patients require treatment, while others can undergo a period watchful waiting without treatment. However, in a small subset of these patients, this slower paced disease can…

A sequential drug treatment approach that can reverse the resistance of leukemia cells to tyrosine kinase inhibitor (TKI) treatment has been developed by scientists at Barts Cancer Institute at Queen Mary University of London. By rewiring the inner workings of the cancer cells and inhibiting a certain enzyme, the team…

Removal of an overexpressed protein known as IGF2BP3 using CRISPR-Cas9 in mice with aggressive leukemia led to improved survival and at least half the mice becoming disease free, show results from a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center. Although the work is still at an…

Research from an international collaboration shows that a single-cell omics approach can identify mutational status and characterize gene expression in hematopoietic stem cells from acute myeloid leukemia patients and successfully identify disease causing cells. Treatments exist for acute myeloid leukemia (AML), but while these often succeed initially, patients often relapse.…

Fluxion Biosciences has launched three new targeted NGS liquid biopsy panels: Spotlight Myeloid, Spotlight EGFR, and Spotlight TP53. The new panels complement the company’s Spotlight 59 pan-cancer panel, and have been validated with Fluxion’s ERASE-Seq variant caller. Spotlight Myeloid is a 478-amplicon panel covering 23 clinically-relevant genes implicated in acute…